[A18-24] Guselkumab (plaque psoriasis) - Addendum to Commission A17-60
Last updated 17.05.2018
Project no.:
A18-24
Commission:
Commission awarded on 09.04.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Adults with moderate to severe plaque psoriasis with inadequate response to other systemic treatments or with contraindication or intolerance
Based on the study data subsequently submitted, there is now proof of a major added benefit in this therapeutic indication
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-60 | Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-05-17 A G-BA decision was published.